(Q96685273)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

27 June 2020

title

Inhibition of SARS-CoV-2 by type I and type III interferons (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

27 June 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

27 June 2020

Friedemann Weber

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

27 June 2020

7

Christian Drosten

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

27 June 2020

Andreas Schoen

2

0 references

Hans Henrik Gad

object named as

Hans Henrik Gad

3

0 references

Rune Hartmann

object named as

Rune Hartmann

4

0 references

author name string

Andreas R Schaubmar

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

27 June 2020

Klaus Failing

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

27 June 2020

publication date

25 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

Journal of Biological Chemistry

27 June 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:32587093%20AND%20SRC:MED&resulttype=core&format=json

The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2

27 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Shared and Distinct Functions of Type I and Type III Interferons

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Guarding the frontiers: the biology of type III interferons

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Interferon-λ orchestrates innate and adaptive mucosal immune responses

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Meeting Overview: Interferon Lambda-Disease Impact and Therapeutic Potential

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Type I Interferon in Chronic Virus Infection and Cancer.

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Treatment of SARS with human interferons

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Efficient replication of the novel human betacoronavirus EMC on primary human epithelium highlights its zoonotic potential

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Interaction of SARS and MERS Coronaviruses with the Antiviral Interferon Response.

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: implications for immunisation policy.

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Severe acute respiratory syndrome-related coronavirus is inhibited by interferon- alpha

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Human cell tropism and innate immune system interactions of human respiratory coronavirus EMC compared to those of severe acute respiratory syndrome coronavirus

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Coronavirus Spike Protein and Tropism Changes

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Differential induction of interferon stimulated genes between type I and type III interferons is independent of interferon receptor abundance

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Interferon lambda 4 signals via the IFNλ receptor to regulate antiviral activity against HCV and coronaviruses

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

COVID-19 and emerging viral infections: The case for interferon lambda

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Comprehensive analysis of kinase inhibitor selectivity

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Alpha/beta interferon (IFN-alpha/beta)-independent induction of IFN-lambda1 (interleukin-29) in response to Hantaan virus infection

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

SARS-CoV-2 is sensitive to type I interferon pretreatment

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Potent Antiviral Activities of Type I Interferons to SARS-CoV-2 Infection

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Critical role of type III interferon in controlling SARS-CoV-2 infection, replication and spread in primary human intestinal epithelial cells

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice.

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Pegylated interferon-alpha protects type 1 pneumocytes against SARS coronavirus infection in macaques

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Combined action of type I and type III interferon restricts initial replication of severe acute respiratory syndrome coronavirus in the lung but fails to inhibit systemic virus spread

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study.

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

SARS: systematic review of treatment effects

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Disease-promoting effects of type I interferons in viral, bacterial, and coinfections

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

COVID-19: combining antiviral and anti-inflammatory treatments

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Side effects of ruxolitinib in patients with SARS-CoV-2 infection: two case reports

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Identification of a novel coronavirus in patients with severe acute respiratory syndrome

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

A recombinant human interferon-alpha B/D hybrid with a broad host-range

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

The Influence of the rs30461 Single Nucleotide Polymorphism on IFN-λ1 Activity and Secretion

28 December 2020

1 reference

https://api.crossref.org/works/10.1074/JBC.AC120.013788

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

28 December 2020

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7549028

Antiviral activities of type I interferons to SARS-CoV-2 infection

10 February 2021

1 reference

PubMed Central

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=7549028

The antiviral effect of interferon-beta against SARS-coronavirus is not mediated by MxA protein

10 February 2021

1 reference

PubMed Central